An oral presentation at the Society for Maternal-Fetal Medicine’s (SMFM) 42nd Annual Pregnancy Meeting explored possible associations with marijuana use and nausea and vomiting in early pregnancy.
An oral presentation at the Society for Maternal-Fetal Medicine’s (SMFM) 42nd Annual Pregnancy Meeting explored possible associations with marijuana use and nausea and vomiting in early pregnancy.1
Cannabis use is increasing as many states legalize marijuana. Despite recommendations from the American College of Obstetrics and Gynecology, pregnant individuals frequently use marijuana to alleviate stress, anxiety, nausea, vomiting, and pain.2 In a 2019 study, researchers conducted a test in which a “mystery caller” contacted 400 Colorado dispensaries to ask about morning sickness relief. Nearly 70% recommended cannabis use, despite a lack of scientific data.3
To further investigate the use of marijuana for morning sickness, Torri D. Metz, MD, MSCR, associate professor at the University of Utah Health in Salt Lake City, Utah, along with her co-authors, led an ancillary study to evaluate whether marijuana use was in fact associated with early pregnancy nausea and vomiting. Secondarily, they wanted to learn more about antiemetic use in individuals with and without marijuana use.4
The ancillary study used data from the prospective Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b), which recruited individuals from 2010 to 2013 from 8 US centers.
Metz and her team included only individuals who completed a Pregnancy-Unique Quantification of Emesis (PUQE) evaluation and consented to a frozen stored urine sample at the first study visit, which included 9,250 participants. Their primary outcome was the overall PUQE score, which involved 3 questions—how many hours in the past 12 hours have you felt nauseated? How many times in the past 12 hours have you vomited? How many times in the past 12 hours have you had retching or dry heaves?
Using the PUQE scores, they calculated nausea severity as mild, moderate, or severe—a PUQE score of 0 meant no nausea severity; A score of 1 to 6 was mild; 7 to 12 was moderate; and a score of 13 or more was qualified as severe. They also gathered antiemetic use via medical inventory that certified research staff collected at the time of the study.
Marijuana exposure was measured via biological sampling. Researchers did an immunoassay screen for 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC), followed by confirmatory testing with liquid chromatography-mass spectrometry with a cutoff at 15 ng/mL. They then quantified the THC in the urine and normalized it with urine creatinine. The team compared those with and without urine positive for THC. Multivariable logistic regression adjusted for maternal age, body mass index, prescription antiemetic use, and gestational age (P<0.05).
Researchers ultimately included 9,250 nuMoM2b participants in their analysis, 5.8% (95% CI 5.4-6.3%) of which were THC-positive (n=540). As for nausea severity, 46% (4,257) had no nausea symptoms; 38.2% (3,531) had mild nausea; and 15.8% (1,462) had moderate-to-severe nausea. The average gestational age at the first visit was between 11- and 12-week gestation.
THC-positive participants had higher rates of nausea symptoms, episodes of vomiting, and episodes of dry heaves than those who tested negative for THC (n=8,710). THC-positive participants, Metz said, were more likely to be younger, Black, live below the poverty line, and have public insurance. Interestingly, after multivariable modeling, incrementally higher THC was not significantly associated with any level of nausea (OR 1.6). 9.6% of participants reported using antiemetics at the first visit. THC-positive participants were more likely to report use of antiemetic (18 vs 12 with P<0.01).
The investigators concluded that, though they were unable to establish cause and effect through a retrospective study, they did find marijuana use to be associated with nausea and vomiting in early pregnancy. They also found that most THC-positive participants were taking only 1 antiemetic.
“Obstetricians should query about marijuana use,” Metz said, “to understand the reasons for use, and counsel [patients on] potential adverse effects. Nausea may be undertreated in early pregnancy, and we do have the opportunity to offer safe, effective alternatives.”
References
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Expert consensus sheds light on diagnosis and management of vasa previa
December 5th 2024A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.
Read More
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Reduced subsequent births reported after severe maternal morbidity
November 26th 2024Women experiencing severe maternal morbidity during their first pregnancy face significantly lower odds of subsequent births, emphasizing the need for personalized reproductive counseling and ongoing monitoring.
Read More